Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis | Zendy

Alaa Badawi | Zendy; Seung Gwan Ryoo | Zendy

Open Access

Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis

Author(s) -

Alaa Badawi,

Seung Gwan Ryoo

Publication year - 2016

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2016.06.015

Subject(s) - middle east respiratory syndrome coronavirus , medicine , middle east respiratory syndrome , meta analysis , vaccination , proinflammatory cytokine , immunology , diabetes mellitus , coronavirus , respiratory system , immune system , obesity , covid-19 , disease , inflammation , infectious disease (medical specialty) , endocrinology

The Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with life-threatening severe illnesses and a mortality rate of approximately 35%, particularly in patients with underlying comorbidities. A systematic analysis of 637 MERS-CoV cases suggests that diabetes and hypertension are equally prevalent in approximately 50% of the patients. Cardiac diseases are present in 30% and obesity in 16% of the cases. These conditions down-regulate the synthesis of proinflammatory cytokines and impair the host's innate and humoral immune systems. In conclusion, protection against MERS-CoV and other respiratory infections can be improved if public health vaccination strategies are tailored to target persons with chronic disorders.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research